These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 9456302)
1. Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7, after intravenous and oral administration to rats, rabbits, and dogs. Yoon WH; Yoo JK; Lee JW; Shim CK; Lee MG Drug Metab Dispos; 1998 Feb; 26(2):152-63. PubMed ID: 9456302 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous determination of a new hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7 in plasma and urine by high-performance liquid chromatography. Yoon WH; Yoo JK; Lee JW; Shim CK; Lee MG Res Commun Mol Pathol Pharmacol; 1998 Jan; 99(1):117-24. PubMed ID: 9523359 [TBL] [Abstract][Full Text] [Related]
3. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats. Kim J; Han KS; Lee JW; Lee MG Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504 [TBL] [Abstract][Full Text] [Related]
4. Effect of food on the pharmacokinetics of YH439 and its metabolites in rats. Kim MK; Ahn BN; Yoo JK; Lee JW Arch Pharm Res; 1997 Dec; 20(6):629-32. PubMed ID: 18982270 [TBL] [Abstract][Full Text] [Related]
5. Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. Shim HJ; Kim YC; Lee JH; Park KJ; Kwon JW; Kim WB; Lee MG Biopharm Drug Dispos; 2005 May; 26(4):161-6. PubMed ID: 15803515 [TBL] [Abstract][Full Text] [Related]
6. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427 [TBL] [Abstract][Full Text] [Related]
7. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Krieter PA; Colletti AE; Doss GA; Miller RR Drug Metab Dispos; 1994; 22(4):625-30. PubMed ID: 7956739 [TBL] [Abstract][Full Text] [Related]
8. Stability, blood partition, and pharmacokinetics of a new reversible proton pump inhibitor, YJA-20379-1. Kim SH; Han KS; Choi WS; Chang MS; Lee MG Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):77-84. PubMed ID: 9434317 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats. Chung HJ; Choi YH; Choi HD; Jang JM; Shim HJ; Yoo M; Kwon JW; Lee MG Eur J Pharm Sci; 2006 Mar; 27(4):363-74. PubMed ID: 16387482 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir. Choi WS; Im GJ; Kim DK; Kim TK; Jung I; Kim TS; Lee SJ; Lee N; Kim YW; Kim JS; Chang K Drug Metab Dispos; 2001 Jul; 29(7):945-9. PubMed ID: 11408358 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects. Han KS; Lee MG Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. Ramanathan-Girish S; Catz P; Creek MR; Wu B; Thomas D; Krogstad DJ; De D; Mirsalis JC; Green CE Int J Toxicol; 2004; 23(3):179-89. PubMed ID: 15204721 [TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice. Beland FA Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702 [TBL] [Abstract][Full Text] [Related]
15. Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers. Species comparison and allometric scaling. Feng MR; Loo J; Wright J Drug Metab Dispos; 1998 Oct; 26(10):982-8. PubMed ID: 9763403 [TBL] [Abstract][Full Text] [Related]
16. Thermal reversible microemulsion system for poorly water-soluble YH439 for oral delivery. Han DH; Jin ZH; Jin YZ; Yin XZ; Shen YY; Gao ZG Chem Pharm Bull (Tokyo); 2010 Jan; 58(1):11-5. PubMed ID: 20045958 [TBL] [Abstract][Full Text] [Related]
17. Hydroxypropyl-beta-cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. Zuo Z; Tam YK; Diakur J; Wiebe LI J Pharm Pharm Sci; 2002; 5(3):292-8. PubMed ID: 12553899 [TBL] [Abstract][Full Text] [Related]
18. Subacute toxicity and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs. Han J; Shin HC; Kim JC; Kim B Food Chem Toxicol; 2004 Mar; 42(3):373-80. PubMed ID: 14871579 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats. Zhong DF; Li K; Xu JH; Du Y; Zhang YF Acta Pharmacol Sin; 2003 Mar; 24(3):256-62. PubMed ID: 12617776 [TBL] [Abstract][Full Text] [Related]
20. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]